lenalidomida labormed 5 mg
pharmadox healthcare ltd. - malta - lenalidomidum - caps. - 5mg - imunosupresoare alte imunosupresoare
lenalidomida labormed 7,5 mg
pharmadox healthcare ltd. - malta - lenalidomidum - caps. - 7,5mg - imunosupresoare alte imunosupresoare
lenalidomida grindeks 10 mg
as grindeks - letonia - lenalidomidum - caps. - 10mg - imunosupresoare alte imunosupresoare
lenalidomida grindeks 15 mg
as grindeks - letonia - lenalidomidum - caps. - 15mg - imunosupresoare alte imunosupresoare
lenalidomida grindeks 2,5 mg
as grindeks - letonia - lenalidomidum - caps. - 2,5mg - imunosupresoare alte imunosupresoare
lenalidomida grindeks 20 mg
as grindeks - letonia - lenalidomidum - caps. - 20mg - imunosupresoare alte imunosupresoare
lenalidomida grindeks 25 mg
as grindeks - letonia - lenalidomidum - caps. - 25mg - imunosupresoare alte imunosupresoare
lenalidomida grindeks 5 mg
as grindeks - letonia - lenalidomidum - caps. - 5mg - imunosupresoare alte imunosupresoare
lenalidomida grindeks 7,5 mg
as grindeks - letonia - lenalidomidum - caps. - 7,5mg - imunosupresoare alte imunosupresoare
minjuvi
incyte biosciences distribution b.v. - tafasitamab - lymphoma, large b-cell, diffuse - agenți antineoplazici - minjuvi is indicated in combination with lenalidomide followed by minjuvi monotherapy for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) who are not eligible for autologous stem cell transplant (asct).